1. Pink Sheet

Industry Refuses To Let Congress Forget PASTEUR Act

 
• By Brenda Sandburg

Melinta CEO and a representative of the Infectious Diseases Society of America call on a Senate HELP subcommittee to push for passage of PASTEUR Act. Introduced in the Senate and House for the third time this year, the measure would establish a subscription model to pay drug developers upfront for certain antimicrobials.

Antibiotic resistance
Congress renews the push for legislation to incentivize development of drugs to tackle antibiotic resistance. • Source: Shutterstock

A subcommittee of the Senate Health, Education, Labor and Pensions Committee held a hearing to spotlight antimicrobial resistance and seek advice on ameliorating the crisis. Witnesses urged the committee to advance the PASTEUR Act, which provides a subscription model to incentivize development of new drugs.

“The most important thing this subcommittee can do is to advance a policy to establish a pull incentive, such as a subscription model, to spur the discovery and development of novel antimicrobials,” Helen Boucher, dean of Tufts University School of Medicine,

More from Legislation

More from Pink Sheet

Global Pharma Guidance Tracker - April 2025

 
• By Vibha Sharma and Anabel Costa-Ferreira

Stay up to date on regulatory guidelines from around the world with the Pink Sheet’s Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.

Medicare Negotiation Does Not Violate Due Process, Appeals Court Rules, Other Suits At Risk

 
• By Cathy Kelly

Decision in AstraZeneca’s lawsuit against the Health and Human Services Department is a precedent-setting victory for the government and a blow to manufacturer efforts to block the price negotiation program.

Keep Talking: US FDA’s Beleaguered Biologics Center Remains Vital To Regenerative Medicine

 
• By Bridget Silverman

Advisory committee for Capricor’s deriamocel planned, regenerative medicine advanced therapy designations proliferate for osteoarthritis, and the ranks of dual RMAT/breakthrough therapy designation holders grow.